Drugs / PACE CART19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05037669 | Jul 2022 → Jan 2025 | B-cell chronic lymphocytic leukemia | University of Pennsylvania | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PACE CART19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05037669 ↗ |
| Modality | Cell therapy | “PACE CART19 cells are allogeneic T cells” NCT05037669 ↗ |
| Route | Intravenous | “PACE CART19 cells will be administered by IV infusion” NCT05037669 ↗ |
| Target | CD19 | “expressing CD19-targeting chimeric antigen receptors” NCT05037669 ↗ |
| Target | TRAC | “TCR-α chain (TRAC) targeted disruption” NCT05037669 ↗ |